jt001
Showing 1 - 5 of 5
A Real-World Study of JT001 for COVID-19
Recruiting
- COVID-19
- JT001
-
Beijing, Beijing, China
- +5 more
Nov 20, 2023
Mild to Moderate COVID-19 Trial in China (JT001, Placebo)
Recruiting
- Mild to Moderate COVID-19
- JT001
- Placebo
-
Fuzhou, Fujian, China
- +8 more
Nov 17, 2022
Moderate to Severe COVID-19 Trial in Shanghai, Tashkent (JT001, JT001 , Favipiravir)
Not yet recruiting
- Moderate to Severe COVID-19
- JT001
- +3 more
-
Shanghai, Shanghai, China
- +1 more
Mar 14, 2022
Mild to Moderate COVID-19 Trial in China, Hong Kong (JT001, Placebo)
Recruiting
- Mild to Moderate COVID-19
- JT001
- Placebo
-
Chongqing, Chongqing, China
- +7 more
Apr 4, 2022